Chinese Drug Co. Chief Must Testify In Tainted Valsartan MDL

Law360 (June 22, 2021, 3:57 PM EDT) -- The special master in multidistrict litigation alleging that pharmaceutical companies sold generic drugs containing the active ingredient valsartan that were tainted with carcinogens ruled on Tuesday that the president of Zhejiang Huahai Pharmaceutical Co. Ltd. can't be blocked from giving a deposition in the case.

Special Master Thomas I. Vanaskie, a retired judge, denied a motion from Zhejiang, Huahai US Inc., Prinston Pharmaceutical Inc. and Solco Healthcare US LLC to preclude deposition of Baohua Chen, saying the plaintiffs in the case have shown that he is not a hands-off manager but would have information about the product, the contamination and the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!